Page last updated: 2024-11-05

thalidomide and Brachmann-De Lange Syndrome

thalidomide has been researched along with Brachmann-De Lange Syndrome in 2 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Sanchez, AC1
Thren, ED1
Iovine, MK1
Skibbens, RV1
Achs, R1
Harper, RG1

Reviews

1 review available for thalidomide and Brachmann-De Lange Syndrome

ArticleYear
Dermatoglyphics.
    American journal of obstetrics and gynecology, 1968, Aug-01, Volume: 101, Issue:7

    Topics: Abnormalities, Drug-Induced; Anemia, Sickle Cell; Anencephaly; Cerebral Palsy; Chromosome Aberration

1968

Other Studies

1 other study available for thalidomide and Brachmann-De Lange Syndrome

ArticleYear
Esco2 and cohesin regulate CRL4 ubiquitin ligase
    Cell cycle (Georgetown, Tex.), 2022, Volume: 21, Issue:5

    Topics: Acetyltransferases; Cell Cycle Proteins; Chromosomal Proteins, Non-Histone; Cohesins; Craniofacial A

2022